Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kyowa Kirin CoKYKOF 83 Shiller PE Ratio is 23.94 as of Sep. 12, 2026, which is 35% below its 10-year median of 37.00. GuruFocus rates KYKOF with a GF Score™ of 83/100 and a GF Value™ of $20.29 (Fairly Valued). Among 527 Drug Manufacturers companies, Kyowa Kirin Co ranks worse than 189753.13% on this metric.
As of today (2026-09-12), Kyowa Kirin Co's current share price is $15.80. Kyowa Kirin Co's E10 for the quarter that ended in Jun. 2026 was $0.66. Kyowa Kirin Co's Shiller PE Ratio for today is 23.94.
The historical rank and industry rank for Kyowa Kirin Co's Shiller PE Ratio or its related term are showing as below:
KYKOF'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.63 Med: 37 Max: 60.48
Current: 18.63
During the past years, Kyowa Kirin Co's highest Shiller PE Ratio was 60.48. The lowest was 18.63. And the median was 37.00.
KYKOF's Shiller PE Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 25.51
vs KYKOF: 18.63
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Kyowa Kirin Co's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.221. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.66 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Kyowa Kirin Co (OTCPK:KYKOF) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Kyowa Kirin Co Shiller PE Ratio Related Terms
Kyowa Kirin Co Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Kyowa Kirin Co's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kyowa Kirin Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kyowa Kirin Co Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kyowa Kirin Co's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Kyowa Kirin Co's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Kyowa Kirin Co's Shiller PE Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kyowa Kirin Co's E10 for the quarter that ended in Jun. 2026 is calculated as:
For example, Kyowa Kirin Co's adjusted earnings per share data for the three months ended in Jun. 2026 was:
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Kyowa Kirin Co (KYKOF) has a Shiller PE Ratio of 23.94 as of Sep. 12, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Kyowa Kirin Co and its competitors. This is 35% below median its historical median of 37.00. Over the past decade, Kyowa Kirin Co's Shiller PE Ratio has ranged from 18.63 to 60.48. According to the industry distribution chart, Kyowa Kirin Co ranks #999999 out of 527 companies in the Drug Manufacturers industry.
Is Kyowa Kirin Co's Shiller PE Ratio too high?
Kyowa Kirin Co's current Shiller PE Ratio of 23.94 is 35% below median its 10-year median of 37.00. Over the past 10 years, this metric has ranged from a low of 18.63 to a high of 60.48. The Drug Manufacturers industry median Shiller PE Ratio is 25.51. Kyowa Kirin Co's value of 23.94 is 6.2% below this industry median. Based on the distribution chart, Kyowa Kirin Co ranks #999999 out of 527 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kyowa Kirin Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kyowa Kirin Co's Shiller PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Kyowa Kirin Co ranks #999999 out of 527 companies for Shiller PE Ratio. This places Kyowa Kirin Co in the lower half of its industry. The industry median Shiller PE Ratio is 25.51. Kyowa Kirin Co's value of 23.94 is 6.2% below this benchmark. Historically, Kyowa Kirin Co's own Shiller PE Ratio has ranged from 18.63 to 60.48 over the past decade. While the company's 10-year median is 37.00 vs. the industry median of 25.51, Kyowa Kirin Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 25.51, based on 527 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kyowa Kirin Co's current Shiller PE Ratio of 23.94 is 6.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Kyowa Kirin Co and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 25.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kyowa Kirin Co's current Shiller PE Ratio is 23.94, which is 35% below median its own 10-year median of 37.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyowa Kirin Co stock overvalued right now?
Based on GuruFocus' analysis, Kyowa Kirin Co (KYKOF) is currently considered Fairly Valued. The stock's GF Value™ is $20.29, compared to a current price of $15.80 — trading 22.1% below its estimated fair value. The current Shiller PE Ratio is 23.94, which is 35% below median its 10-year median of 37.00 and 6.2% below the Drug Manufacturers industry median of 25.51. Kyowa Kirin Co's overall GF Score™ is 83/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Kyowa Kirin Co (KYKOF), the current Shiller PE Ratio is 23.94 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kyowa Kirin Co (KYKOF) Overvalued in 2026?
Based on GuruFocus' analysis, Kyowa Kirin Co stock appears to be undervalued.
The current stock price of $15.80 is trading 22.1% below its estimated GF Value™ of $20.29.
GuruFocus considers Kyowa Kirin Co to be Fairly Valued.
Key valuation signals for KYKOF:
Shiller PE Ratio: 23.94 (35% below median its 10-year median of 37.00)
GF Value™: $20.29 vs. price of $15.80 (22.1% below fair value)
Industry Position: 6.2% below the Drug Manufacturers median (#999999 of 527)
No single metric tells the full story. See the KYKOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kyowa Kirin Co Ltd is engaged in research, development, manufacturing, sales, import and export of prescription pharmaceuticals. Its products include KHK4083/AMG 451, rocatinlimab; ziftomenib; OTL-203 KK8398, infigratinib; KHK4951, tivozanib; OTL-201; KK4277; KK2260; KK2269; KK2845; and KK8123.
83GF Score
Get the complete analysis for KYKOF
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KYKOF has been successfully added to your 
